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Abstract
Catechol-O-methyltransferase, encoded by COMT gene, is the primary enzyme that metabolizes
catecholamines. COMT haplotypes have been associated with vulnerability to persistent non-
traumatic pain. In this prospective observational study, we investigated the influence of COMT on
persistent pain and pain interference with life functions after motor vehicle collision (MVC) in
859 European American adults for whom overall pain (0–10 numeric rating scale) and pain
interference (Brief Pain Inventory) were assessed at week 6 after MVC. Ten single nucleotide
polymorphisms (SNPs) spanning the COMT gene were successfully genotyped, nine were present
in three haploblocks: block 1 (rs2020917, rs737865, rs1544325), block 2 (rs4633, rs4818, rs4680,
rs165774) and block 3 (rs174697, rs165599). After adjustment for multiple comparisons,
haplotype TCG from block 1 predicted decreased pain interference (p =.004). The pain-protective
effect of the low pain sensitivity (LPS, CGGG) haplotype from block 2 was only observed if at
least one TCG haplotype was present in block 1 (haplotype × haplotype interaction p=.002 and <.
0001 for pain and pain interference, respectively). Haplotype AG from block 3 was associated
with pain and interference in males only (sex × haplotype interaction p=.005 and .0005,
respectively). These results suggest that genetic variants in the distal promoter are important
contributors to the development of persistent pain after MVC, directly and via the interaction with
haplotypes in the coding region of the gene.
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INTRODUCTION
COMT has been shown to influence an array of complex phenotypes, including pain
phenotypes (Nackley et al. 2006b; Diatchenko et al. 2005; Meyer-Lindenberg et al. 2006;
Zubieta et al. 2003; Smolka et al. 2007; Reuter and Hennig 2005). Initially it was widely
assumed that variations in COMT activity in humans were caused only by the non-
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synonymous valine (Val) to methionine (Met) substitution at codon 158 (rs4680), which
results in reduced thermostability and reduced activity of the enzyme (Lotta et al. 1995).
Numerous studies identified associations between the low-activity Met158 allele and several
pain phenotypes (e.g. (Smith et al. 2011; Cohen et al. 2009; Barbosa et al. 2012; Jacobsen et
al. 2012; van Meurs et al. 2009; Gursoy et al. 2003)), however the observed associations
were often modest and occasionally inconsistent (Tander et al. 2008; Hocking et al. 2010;
Nicholl et al. 2010), suggesting that additional SNPs in the COMT gene modulate COMT
activity.
In a study examining the association between COMT genotypes in the central haploblock of
the COMT gene and variability in human pain perception, the Val158Met polymorphism
alone was not significantly associated with pain sensitivity (Diatchenko et al. 2005). Instead,
three common haplotypes in the central haploblock, including two synonymous SNPs
(rs4633 and 4818) and the nonsynonymous Val158Met SNP, were found to code for
different levels of enzymatic activity and influence vulnerability to persistent
musculoskeletal pain (Diatchenko et al. 2005). These differences in COMT enzyme activity
were subsequently demonstrated to be mediated by haplotype-dependent differences in
secondary RNA structure (Nackley et al. 2006a). The robust effect of these haplotype-
dependent differences in secondary RNA structure on COMT enzyme activity was found to
be much greater than the modest effect of the Val158Met substitution alone (Nackley et al.
2006a).
Despite these data, studies examining the association between COMT haplotypes in the
central haploblock of the COMT gene and persistent musculoskeletal pain outcomes have
produced inconsistent results. While COMT haplotypes predicted fibromyalgia symptom
severity in Spanish (but not Mexican) women (Vargas-Alarcon et al. 2007), two other
population-based studies failed to demonstrate an association of COMT haplotypes and
chronic widespread pain (Hocking et al. 2010; Nicholl et al. 2010). One potential contributor
to these inconsistent results may be that important interactions exist between these
haplotypes and other variants in COMT. This hypothesis is supported by evidence that
COMT variants outside the central haploblock, including variants in the distal promoter (P2)
region and 3′-untranslated region, influence complex phenotypes (Meyer-Lindenberg et al.
2006; Shifman et al. 2002; Gaysina et al. 2013; Shibata et al. 2009). Another potential
contributor to inconsistent findings in previous association studies evaluating haplotypes in
the central COMT haploblock may be sex-specific effects. Evidence suggests that important
differences in the influence of COMT genotypes may exist between men and women
(reviewed in (Tunbridge and Harrison 2011)).
In this prospective study we evaluated the influence of haplotypes from three functionally
important COMT loci (promoter P2, coding region, and 3′-untranslated region) on
vulnerability to persistent pain 6 weeks after motor vehicle collision (MVC). We
hypothesized that COMT haplotypes, and/or interactions between haplotypes from these
three loci and patient sex, would influence pain severity six weeks after experiencing an
MVC. In addition, because pain-related interference with global life function is an important
health outcome in patients with pain,(Dworkin et al. 2005) and because COMT may
influence not only pain severity but also psychological processes that influence function in
the presence of pain (George et al. 2008b; George et al. 2008a), we also evaluated the
influence of these haplotypes on pain-related interference six weeks after MVC.
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The details of the CRASH study have been reported (Platts-Mills et al. 2011). In brief,
individuals ≥ 18 and ≤ 65 years of age presenting to one of eight emergency departments in
four no-fault insurance states within 24 hours of MVC who did not have fracture or other
injury requiring hospital admission were enrolled. Patients who were not alert and oriented
were excluded, as were pregnant patients, prisoners, patients unable to read and understand
English, patients taking a β-adrenoreceptor antagonist, or patients taking opioids above a
total daily dose of 30 mg of oral morphine or equivalent. Participant race was determined
via self-report. Enrollment was limited to non-Hispanic whites (the most common ethnicity
at study sites) because the study included the collection of genetic data and genetic analyses
are potentially biased by population stratification (Diatchenko et al. 2007). Informed consent
was obtained from all participants and IRB approval was obtained at all study sites.
DNA collection and genotyping
Blood (8.5cc) was collected using PAXgene DNA storage tubes. Blood samples were then
refrigerated at the study site and shipped in batches every 2 weeks to Beckman Coulter
Genomics, Inc, Morrisville, NC. DNA purification was performed using PAXgene™ blood
DNA kit (Qiagen, Valencia, CA). Average DNA yield was 275 μg per sample. Genotyping
was performed at batches using the Sequenom platform (Sequenom, Inc., San Diego, CA).
Two Hapmap samples and 2 repeat samples were included in each genotyping batch (96
samples) to ensure genotypic accuracy and reliability. Repeated genotyping demonstrated
greater than 98% call agreement.
Outcome assessments
Overall pain intensity six weeks after MVC (defined in this study as “persistent pain”) was
assessed via telephone interview or web-based questionnaire using a verbal 0–10 numeric
rating scale (NRS) assessing average overall pain intensity during the past week. Verbally
administered NRSs have been validated as a substitute for Visual Analog Scales in acute
pain measurement in the emergency department (Bijur et al. 2003).
Pain interference with life functions was assessed using the Brief Pain Inventory (BPI)
(Cleeland and Ryan 1994; Keller et al. 2004). Interference with each life function (general
activity, walking ability, mood, relations with other people, sleep and enjoyment of life) was
assessed on a scale from 0 to 10, where 0 represents “does not interfere” and 10 indicates
“interferes completely”. Interference total score was calculated by adding up
interferencesubscale values for each individual.
Analyses
All genotyped SNPs were tested for Hardy-Weinberg equilibrium (HWE) using a chi-square
test. SNPs that were not in HWE, SNPs with call rates below 85%, and SNPs with minor
allele frequency less than 0.05 were excluded from analyses.
Linkage disequilibrium between COMT SNPs was explored by calculating Levontin D′ and
squared correlation r2 using HaploView (Barrett et al. 2005). Haploblocks were estimated
using the method of confidence intervals (Gabriel et al. 2002). COMT haplotypes and their
population frequencies were estimated using the expectation-maximization algorithm
implemented in HaploView and were then verified using Bayesian estimation of haplotype
frequencies implemented in HAPLOTYPE procedure (SAS version 9.2, SAS Institute, Cary,
NC) (Lin et al. 2002).
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The associations between COMT haplotypes and pain outcomes in the CRASH cohort were
assessed using general linear models. Study site was included as a covariate in these models
due to potential genetic heterogeneity between study recruitment centers. Interaction
between haplotypes and interaction between haplotypes and patient sex were assessed by
introducing the corresponding product terms into the models. Partial F-test was used to
evaluate whether the removal of the non-significant terms affected model fit. Least square
means were output from the model and post-hoc pairwise comparisons of means were
performed. Bonferroni correction of the significance level was performed by dividing 0.05
by the number of estimated haplotypes.
RESULTS
Study population
A total of 10,629 individuals who presented to the emergency department for evaluation in
the hours after MVC were screened, 1,416 were eligible, 969 consented to study
participation, and 948 completed baseline evaluation. The recruitment flowchart, with major
reasons for ineligibility and refusal, is shown in Supplementary Figure 1. Nine hundred and
forty five individuals were successfully genotyped, 6 week follow-up evaluation was
obtained in 859/945 (91%). Participants who were lost to follow-up were more likely to be
younger, less-educated males; they did not, however, were different from the rest of the
cohort in terms of baseline pain severity (Table 1).
Genotyping results and haplotype estimation
Ten SNPs spanning the COMT gene were genotyped. Call rates were excellent (≥99.9%) for
nine SNPs and good for rs165599 (96.4%). All SNPs were in Hardy-Weinberg equilibrium
(Chi-square p > .05, Supplementary Table 1). Using data from all 945 genotyped DNA
samples, three haploblocks were identified by the method of confidence intervals (Gabriel et
al. 2002) (Figure 1, A). Haploblocks 1, 2, and 3 included three, four, and three common
haplotypes, respectively (Figure 1, B). Haplotypes in block 1 were denoted as A1–A3;
haplotypes in block 3 were denoted as B1–B3. Haplotypes in block 2 corresponded to those
identified in a previous study (Diatchenko et al. 2005) and included the low pain sensitivity
(LPS) haplotype, the high pain sensitivity (HPS) haplotype, and two variants of the average
pain sensitivity (APS1 and APS2) haplotype (Table 2).
Haplotype frequencies were estimated using the Expectation-Maximization algorithm;
verification using Bayesian estimation yielded virtually identical results (data not shown).
Within each block, the above described common haplotypes accounted for approximately
99% of haplotypic diversity. Haplotype pair assignment probability for blocks 1, 2, and 3
was greater than .99 in 943, 941, and 911 individuals, respectively. Because haplotype
uncertainty in a small proportion of individuals (<5% of the total sample) is unlikely to
substantially bias study results (Kraft and Stram 2007), for further analyses these individuals
were assigned to the most probable haplotype pair.
Bivariate analyses evaluating associations between COMT haplotype and persistent pain
and pain interference 6 weeks after MVC
Under the genotypic model adjusted for study site, LPS haplotype was significantly
protective against persistent pain at the nominal level alpha = 0.05 (Table 2). Three
haplotypes were associated with increased pain interference at the nominal level alpha =
0.05: LPS, haplotype A3, and haplotype B2. After applying Bonferroni correction
(alpha=0.05/10=0.005), only A3 remained a significant (p=0.004) predictor of pain
interference. Individuals heterozygous at the A3 allele had the highest pain interference,
Bortsov et al. Page 4













those homozygous had the lowest pain interference, and individuals without a haplotype A3
had an intermediate phenotype.
Multivariate analyses including haplotype × haplotype and haplotype × sex interactions
Multivariate regression analyses with interaction terms were used to evaluate the potential
influence of haplotype × haplotype and haplotype × sex interactions on pain and pain-related
interference outcomes. Haplotypes associated at the p < 0.05 level with pain and pain-related
interference outcomes in bivariate analyses (A3, LPS, and B2), sex, study site, and all
possible two-way interactions were included as model terms. Interactions A3×LPS and
B2×Sex were highly significant in both models (Table 3). Removal of non-significant and
borderline-significant interaction terms did not affect the overall fit of the models (partial F-
test p > 0.1), and both interactions (A3×LPS and B2×Sex) remained highly significant
(Table 3).
Subgroup analyses of haplotype×haplotype and haplotype×sex interactions
To better understand the identified A3×LPS interaction, the influence of an LPS allele on
pain-related outcomes was compared among individuals in the MVC cohort with (410, 48%)
and without (445, 52%) at least one A3 allele. Among those with one or more copies of the
A3 allele, LPS haplotype had a nearly linear protective effect on pain-related outcomes,
reducing overall pain severity by 0.8±0.3 units (p=0.002, Figure 2, A) and pain interference
by 5.7±1.6 units (p=0.0004, Figure 2, B) for each LPS allele copy present. In contrast,
among individuals without at least one A3 allele, LPS copy number had no effect on pain or
pain interference (Figure 2).
To evaluate the B2×sex interaction, the effect of B2 haplotype on pain-related outcomes
after MVC was compared among men (321, 37%) and women (538, 63%). Because of the
low frequency of haplotype B2 (5.4%), heterozygous (n=83) and B2/B2 homozygous (n=5)
individuals were combined into one category. Among men, the presence of one or two
copies of haplotype B2 was associated with increased overall pain (by 1.5±0.5 scale units,
p=0.005, Figure 3, A) and increased pain interference (by 12±4 scale units, p=0.0005,
Figure 3, B). In contrast, among women the presence of one or two copies of haplotype B2
had no effect on pain and pain interference (Figure 3).
To explore whether this sex difference in B2 haplotype influence might be limited to pre-
menopausal women, we repeated the analysis among only men and women who were age 55
or older at the time of the MVC (n=108). Although the interaction between B2 haplotype
and sex in this much smaller sample was not statistically significant (p = 0.25 for pain
interference and p = 0.093 for pain), effect sizes were similar (data not shown). These data
suggest that the interaction between B2 haplotype and sex may not be limited to
premenopausal women alone.
DISCUSSION
In this prospective cohort study of adult European Americans presenting to the emergency
department after MVC, COMT haplotype×haplotype and haplotype×sex interactions were
much stronger predictors of pain outcomes 6 weeks after MVC than individual haplotypes.
In the overall cohort, the LPS haplotype in the COMT coding region was nominally
associated with pain and interference, and haplotype A3 in the P2 promoter region predicted
pain interference with a significant overdominant effect. However, as evident from the F-
values in Tables 2 and 3, the interaction of the A3 and LPS haplotypes was much more
strongly associated with pain and pain interference outcomes after MVC than either
haplotype alone. (The fact that the LPS haplotype was largely dependent on distal P2
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promoter genotype suggests that the COMT P2 locus is also functional.) Similarly, the effect
of haplotype B2 in the 3′-untranslated region was associated with increased overall pain and
pain interference after MVC in men, but not in women.
The present finding that COMT distal P2 promoter genotype influences pain outcomes after
MVC is consistent with current understanding of COMT isoform expression and
physiology. The P2 promoter influences MB-COMT expression, and MB-COMT is the
predominant form of the enzyme in the central nervous system (CNS) (Chen et al. 2004).
Thus genetic variants in P2 are most likely to affect the function of important pain pathways
in the CNS. In addition, the MB-COMT isoform also has a higher affinity to catecholamines
at the physiologic concentrations of catecholamines found in the brain (Roth 1992).
Our findings of the interaction between genotypes in the coding region of COMT and
genotypes in the P2 promoter region are in accordance with several previous studies. In a
study examining the influence of COMT polymophisms on brain function, two SNPs in the
P2 region, rs737865 and rs2075507, when analyzed together with the Val158Met
polymorphism, were shown to critically affect prefrontal cortex function (Meyer-Lindenberg
et al. 2006). Of note, allele C at rs737865 is a tagging allele for haplotype A3 in our study
(Figure 1, B) and is in high linkage disequilibrium with HindIII, a potentially functional
deletion in the P2 promoter (Palmatier et al. 2004). In another study, allele C at rs737865
was found to be associated with reduced COMT transcription in the central nervous system
(Bray et al. 2003). Finally, interactions between P2 promoter region genetic variants and the
coding region variants have been associated with vulnerability to schizophrenia (Shifman et
al. 2002).
One of the hypothetical mechanistic explanations of the interaction between promoter P2
variants and coding region haplotypes employs a potentially non-linear relationship between
COMT activity and vulnerability to persistent pain (Figure 4). The non-linear, U-shaped,
dose-response relationship with pain sensitivity has been previously documented for
yohimbine (alpha-adrenoceptor agonist) and dopamine (Paalzow and Paalzow 1983;
Pelissier et al. 2006). The proposed model may help to explain why the effect of COMT
central block haplotypes is prominent with some promoter P2 haplotypes (e.g. low
transcription in presence of haplotype A3 at promoter P2) and non-significant in others.
Additionally, in our study haplotype A3 (previously shown to be associated with reduced
transcription of COMT) (Bray et al. 2003) had significant main effect on pain outcomes,
resulting in substantially higher pain interference in A3/A3 homozygous individuals.
In this study we also observed marked sexual dimorphism in the influence of COMT
genotypes on pain outcomes after motor vehicle collision. The strong effect of the B2
haplotype (covering intron 5, exon 6, and 3′-untranslated region) on pain outcomes was
present only in males. This finding is in accordance with previous studies showing
differences in males and females in COMT function: COMT activity in the prefrontal cortex,
the brain region responsible for cognitive and emotional processing of pain, has been shown
to be higher in males than in females (Chen et al. 2004). These observations are also
supported by animal studies, which found that knocking out the COMT gene results in
increased dopamine in the frontal cortex in males, but not in females (Gogos et al. 1998).
Additionally, genetic variations in COMT have also been shown to have sexually-dimorphic
effects in several neuropsychiatric conditions. COMT Val158Met (rs4680) genotype has
been found to influence the risk of obsessive-compulsive disorder (Pooley et al. 2007;
Katerberg et al. 2010) and Intelligence Quotient (Barnett et al. 2009) in males but not in
females, and COMT genotype (rs737865 and rs165599) has been found to influence
schizophrenia in females, but not in males (Shifman et al. 2002; Talkowski et al. 2008).
While the sexually dimorphic effects of COMT have been attributed to estrogen (a potent
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inhibitor of COMT transcription) (Jiang et al. 2003), in our subgroup analyses of the
participants age 55–65 effect size differences between men and women were unchanged.
This suggests that the sexually dimorphic effects of haplotype B2 may not be due to
estrogen alone.
One of the limitations of our study is that we did not utilize ancestry informative markers to
control for population stratification in our study. However, self-reported race or ethnicity
has been shown to be an accurate means of determining European American ancestry in
genetic association studies (Tang et al. 2005). Additionally, all assessed polymorphisms
were in Hardy-Weinberg equilibrium, suggesting little, if any, stratification in the studied
samples. Adjustment for study site in the regression models was also used to minimize the
effect of population variations across geographic regions of the Eastern United States. In
addition, the results of our study are generalizable only to European Americans, and the
influence of COMT genotype on pain outcomes after other traumatic events is unknown.
Also, as reflected by our use of the term “persistent pain” throughout the manuscript, while
six weeks of pain is an important health outcome in itself, pain of this duration does not yet
meet the definition of chronic (i.e. pain lasting 2–3 months (Wolfe et al. 1990; Macrae and
Davies 1999)). Future studies should evaluate the influence of COMT genotype on chronic
pain, both after MVC and after other types of trauma exposure.
Finally, although we present no replication of our finding of the interaction between COMT
haplotypes, our results are in strong agreement with previous literature on the role of
catechol-O-methyltransferase and its polymorphisms in pain perception and chronic pain
development (Diatchenko et al. 2005; Nackley et al. 2006a; Meyer-Lindenberg et al. 2006;
Shifman et al. 2002; Gaysina et al. 2013; Shibata et al. 2009).
In conclusion, this is the first report of the association between COMT genetic variants and
persistent pain and pain interference after MVC. Our study confirms that the effect of
COMT polymorphisms on persistent pain is best evaluated using a haplotype-based
approach that takes into account interactions between haplotypes in the distal promoter,
coding, and 3′-untranslated region, and sex differences. Further studies are needed to
investigate the biological substrate for these interactions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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(A) COMT haploblocks and linkage disequilibrium; color and numbers represent D′ values
(dark red=high inter-SNP D′; blue=statistically ambiguous high D′; white= statistically
ambiguous low inter-SNP D′). (B) COMT haplotypes and haplotype frequencies; thin lines
denote haplotype combinations with frequency >1%, thick lines with frequency > 10%.
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Haplotype A3 x LPS interactions on overall pain (A) and pain interference (B) at week 6
after motor vehicle collision; plotted values are means ± standard errors of mean; p-values
are from the additive genetic model.
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Haplotype B2 x sex interactions on overall pain (A) and pain interference (B) at week 6 after
motor vehicle collision. Plotted values are means ± standard errors of mean.
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Hypothesized mechanistic explanation of the interaction between P2 promoter and COMT
coding region haplotypes. (A) In presence of the COMT promoter P2 haplotype associated
with low levels of COMT transcription, the effect of the haplotypes covering the coding
region of COMT is prominent because of the steep dose-response curve; (B) In absence of
the “low transcription” P2 haplotype the total enzymatic activity is shifted to the right so that
the effect of the haplotypes in the coding gene region is reduced because of the flattened
dose-response curve.
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Table 1
Characteristics of the study participants
Characteristic Baseline (n=948) Lost to week 6 follow-up (n=89) Week 6 follow-up (n=859)
Mean age, yrs (SD)a 36 (13) 31 (11) 36 (13)
 Range 18–65 18–61 18–65
Females, n (%)a 575 (61) 37 (42) 538 (63)
Education, n (%)a
 8–11 yrs 42 (4) 6 (7) 36 (4)
 HS 184 (19) 27 (31) 157 (18)
 Post-HS 57 (6) 5 (6) 52 (6)
 Some college 311 (33) 34 (39) 278 (32)
 College 237 (25) 13 (15) 225 (26)
 Post-college 113 (12) 3 (3) 110 (13)
Overall pain score (SD) 5.5 (2.4) 5.6 (2.5)b 3.8 (2.8)
Pain severity, n (%)
 None or mild (0–3 NRS) 188 (20) 16 (18)b 417 (49)
 Moderate (4–6 NRS) 407 (43) 37 (42)b 273 (32)
 Severe (7–10 NRS) 344 (37) 36 (40)b 168 (20)
Pain interference (SD)
 Total - - 16.8 (18.1)
 General activity - - 2.8 (3.1)
 Walking ability - - 1.5 (2.6)
 Mood - - 2.9 (3.1)
 Relations with other people - - 1.5 (2.7)
 Sleep - - 2.9 (3.3)
 Enjoyment of life - - 2.3 (3.1)
a
these characteristics were significantly different between those for whom 6 week data were obtained and those who were lost to follow-up (p <
0.05 for t-test or Fisher exact test, as appropriate);
b
baseline measurements; SD, standard deviation; HS, high school; NRS, numeric rating scale




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Neuromolecular Med. Author manuscript; available in PMC 2015 March 01.
